Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements. “We delivered a strong.

Business Wire • May 6, 2026

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.

Zacks Investment Research • May 7, 2026

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.

Zacks Investment Research • Apr 30, 2026

3 Bargain-Cheap Small Caps Worth a Second Look

The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.

MarketBeat • Apr 9, 2026

Analysts See This Pharma Stock Surging 60%; Eyes Fresh Entry

This drug stock has used recent declines as an opportunity to build a bullish base. Analysts see hearty price gains ahead.

Investors Business Daily • Apr 2, 2026

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report. The AMR Benchmark evaluates ph.

Business Wire • Mar 10, 2026

Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Seeking Alpha • Feb 27, 2026

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted select corporate progress and achievements. “202.

Business Wire • Feb 25, 2026

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at.

Business Wire • Feb 19, 2026

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.

MarketBeat • Jan 8, 2026